Clinical Trial: Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095868) titled 'Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors' on July 24.

Brief Summary: Brief Summary:

The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Selected Types of Solid Tumor

Intervention: BIOLOGICAL: EVM14

Cancer Vaccine

COMBINATION_PRODUCT: Pembrolizumab

Anti-PD1 antibody

Recruitment ...